8-K: Profusa Doubles Authorized Shares, Clears Path for Notes

Profusa, Inc. stockholders approved a significant increase in authorized common stock and the potential issuance of shares related to senior secured convertible notes, enhancing future capital flexibility.

Summary

• Stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 300,000,000 shares to 600,000,000 shares.
• The amendment to increase authorized shares was approved with 17,968,659 votes For, 1,140,322 Against, and 20,432 Abstain.
• Stockholders also approved the potential issuance of common stock in excess of 19.99% of outstanding shares upon the conversion of certain senior secured convertible notes, for the purpose of complying with Nasdaq Listing Rule 5635(d).
• The approval for the potential issuance of shares related to convertible notes received 18,296,205 votes For, 858,635 Against, and 4,573 Abstain.
• The amendment to the Certificate of Incorporation became effective on October 20, 2025, upon filing with the Secretary of State of Delaware.
• As of the record date of September 22, 2025, there were 40,859,307 shares of common stock outstanding, with 19,159,413 shares represented at the meeting, constituting a quorum.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the actions provide crucial financial flexibility and compliance, the potential for significant future dilution introduces a degree of caution for existing shareholders.

Positives

• The increase in authorized common stock provides the company with greater flexibility for future capital raises, strategic transactions, or equity compensation plans.
• Shareholder approval for the potential issuance of shares related to convertible notes ensures compliance with Nasdaq listing rules, facilitating the conversion of these notes and potentially strengthening the company's balance sheet by reducing debt.
• The strong majority vote in favor of both proposals indicates solid shareholder support for management's strategic direction and financing plans.

Negatives

• The significant increase in authorized shares from 300 million to 600 million, coupled with the approval for potential issuance related to convertible notes, introduces the risk of substantial future dilution for existing shareholders.
• While necessary for compliance, the approval of issuing shares in excess of 19.99% for convertible notes signals an impending or potential dilution event.

Risks

• Potential significant dilution of existing shareholders' ownership and voting power due to the increased authorized shares and the future issuance of common stock upon conversion of senior secured convertible notes.
• Market perception and potential downward pressure on share price if future capital raises or conversions occur at lower valuations.
• The company's ability to effectively utilize the increased authorized shares for beneficial strategic purposes or capital raises remains a future execution risk.

Future Outlook

The company has significantly increased its authorized common stock, providing substantial flexibility for future capital raises, strategic partnerships, or other corporate purposes requiring equity issuance. The approval for issuing shares related to convertible notes indicates an anticipated conversion event, which could impact the company's capital structure.

Management Comments

• Ben Hwang, Chief Executive Officer, signed the report on behalf of Profusa, Inc.

Industry Context

Increasing authorized shares is a common corporate governance action for growth-oriented companies, particularly those in the biotechnology or medical device sectors like Profusa, Inc., which often require significant capital for research, development, and commercialization. This move positions the company to access capital markets more readily or facilitate strategic transactions, aligning with typical practices for firms seeking to maintain financial flexibility.

Comparison to Industry Standards

• The action of increasing authorized shares is a standard corporate governance practice, particularly for companies that anticipate future capital needs for growth, acquisitions, or debt conversion. Many emerging growth companies in the biotech sector frequently undertake such measures to ensure they have sufficient equity available for financing rounds.
• The approval to issue shares exceeding 19.99% of outstanding stock for convertible notes is a specific requirement under Nasdaq Listing Rule 5635(d), a common hurdle for companies utilizing convertible debt instruments. Successful shareholder approval for this is typical for companies seeking to convert such notes without violating exchange rules.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from future equity issuances and the conversion of convertible notes, but benefit from the company's enhanced financial flexibility and ability to pursue growth initiatives.
• Convertible Noteholders: The approval facilitates the conversion of their notes into common stock, providing a clear path for their investment strategy.
• Management: Gains greater flexibility in capital management and strategic planning.

Next Steps

• The company may proceed with future equity offerings or strategic transactions utilizing the newly authorized shares.
• The company is now positioned to convert the senior secured convertible notes into common stock, subject to the terms of those notes.

Key Dates

Recommendation

The filing details standard corporate governance actions that provide Profusa with necessary financial flexibility and compliance. While the increase in authorized shares and the approval for convertible note conversions are positive for the company's long-term strategic options and debt management, they also introduce the potential for significant future dilution. Investors should hold and monitor subsequent announcements regarding how this increased capacity is utilized, as future capital raises or conversions will directly impact share price and ownership structure.

Keywords

Profusa, common stock, authorized shares, convertible notes, Nasdaq Listing Rule 5635(d), shareholder meeting, capital raise, dilution, corporate governance, amendment, certificate of incorporation